anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Research has highlighted the potential adverse effects of weight bias internalization (WBI) on adolescents, but there has been little examination of WBI and sources of weight teasing (family, peers, or both) or across racial/ethnic diversity of adolescents. We aimed to examine the relationship between WBI and sources of weight teasing across sociodemographic characteristics and weight status in a diverse community sample of adolescents.
METHODS: Data were collected from a U.S. sample of 1859 adolescents aged 10-17 years (59% female; 43% White, 27% Black or African American, and 25% Latino). An online questionnaire was used to assess participants' experiences of weight teasing from family members, peers, or both, and their weight status, weight-related goals, WBI, and sociodemographic characteristics.
RESULTS: Adolescents experiencing weight teasing from both family and peers reported the highest levels of WBI, while those reporting no teasing exhibited the lowest levels. These patterns were observed across sex, race/ethnicity, weight status, and weight goals, and persisted after controlling for depressive symptoms. Notably, family influences played a salient role, with adolescents reporting higher WBI if teased by family only compared to teasing from peers only. Sex and racial differences were also observed in adolescents' experiences with weight-based teasing.
CONCLUSION: Our study reveals associations between adolescent weight-based teasing, WBI, and sociodemographic factors. Weight-based teasing, whether from family and peers or from family only, was associated with increased WBI. Interventions targeting weight stigma in youth should not be limited to peer-focused efforts, but should also emphasize supportive family communication.
Adults (males and females) above the age of 18 yrs will be recruited to determine if they have symptoms of depression based on a questionnaire (Center for Epidemiologic Studies - Depression Scale (CES-D). They will then complete a Beck Inventory before and after the exercise. Participants will be divided into groups either having symptoms of depression or not. They will be randomized to ride on a cycle ergometer with or without using Virtual Reality (VR) that will allow them to view neighborhoods or parks during the exercise. The ergometer will be set at resistance raising the heart rate to 65% of their age-predicted heart rate maximum. They will ride for 20 min and then complete the Beck Inventory to determine any changes in their depressive symptoms.
Participants with Merkel cell carcinoma amenable to complete resection will receive two cycles (6 weeks) of therapy with the combination of lenvatinib plus pembrolizumab and then proceed to planned resection within 2-4 weeks following completion of cycle 2. Following surgical recovery and completion of adjuvant radiation therapy (if indicated), treatment will resume with pembrolizumab monotherapy with intent to complete 17 cycles total of pembrolizumab.
An oral fibrinolytic composition comprising the enzymes serrapeptase and nattokinase. The composition treats and/or may prevent fibrosis conditions and their related symptoms in animals, including humans. This composition may further comprise of one or more enzymes, bioflavonoids, vitamins, coenzymes, minerals, probiotics, prebiotics, herbs, excipients and/or combinations thereof. The composition may improve lung capacity, oxygen saturation, vigor, and/or lung function. It may further alleviate dyspnea, limitations and fear caused by dyspnea, cough, phlegm, fatigue, body pain, chest discomfort, anxiety, depression, loss of appetite, and/or respiratory disorders. The composition of serrapeptase and nattokinase and/or one or more additional component may improve immune health, sleep, health-related quality of life (HRQoL), social well-being, health status, mental health and/or exercise capacity. The present disclosure also provides a method for improving or reducing the frequency and severity of fibrosis and related symptoms in a subject having a fibrotic disease.
After intravenous administration, doxercalciferol is activated by CYP 27 in the liver to form 1α,25-(OH)2D2 (major metabolite) and 1α,24-dihydroxyvitamin D2 (minor metabolite). Activation of doxercalciferol does not require the involvement of the kidneys.

Peak blood levels of 1α,25-(OH)2D2 are reached at 8 +/- 5.9 hours (mean +/- SD) after a single intravenous dose of 5 mcg of doxercalciferol. The mean elimination half-life of 1α,25-(OH)2D2 after an oral dose is approximately 32 to 37 hours with a range of up to 96 hours. The mean elimination half-life in patients with end stage renal disease (ESRD) and in healthy volunteers appears to be similar following an oral dose. Hemodialysis causes a temporary increase in 1α,25-(OH)2D2 mean concentrations presumably due to volume contraction. 1α,25-(OH)2D2 is not removed from blood during hemodialysis.
BACKGROUND: Postoperative nausea and vomiting (PONV) affects patient satisfaction, health care costs, and hospital stay by complicating the postoperative recovery period after adolescent idiopathic scoliosis (AIS) spinal fusion surgery. Our goal was to identify recommendations for optimal management of PONV in AIS patients undergoing posterior spinal fusion (PSF).
METHODS: We performed a systematic review in June 2022, searching the PubMed and Embase electronic databases using search terms "(Adolescent idiopathic scoliosis) AND (Postoperative) AND (Nausea) AND (Vomiting)." Three authors reviewed the 402 abstracts identified from January 1991 to June 2022. Studies that included adolescents or young adults (<21 years) with AIS undergoing PSF were selected for full-text review by consensus. We identified 34 studies reporting on incidence of PONV. Only 6 studies examined PONV as the primary outcome, whereas remaining were reported PONV as a secondary outcome. Journal of Bone and Joint Surgery Grades of recommendation were assigned to potential interventions or clinical practice influencing incidence of PONV with respect to operative period (preoperative, intraoperative, and postoperative period) on the basis that potential guidelines/interventions for PONV can be targeted at those periods.
RESULTS: A total of 11 factors were graded, 5 of which were related to intervention and 6 were clinical practice-related. Eight factors could be classified into the operative period-1 in the intraoperative period and 7 in the postoperative period, whereas the remaining 3 recommendations had overlapping periods. The majority of grades of recommendations given were inconclusive or conflicting. The statement that neuraxial and postoperative systemic-only opioid therapy have a similar incidence of PONV was supported by good (Grade A) evidence. There was fair (Grade B) and poor evidence (Grade C) to avoid opioid antagonists and nonopioid local analgesia using wound catheters as PONV-reducing measures.
CONCLUSION: Although outcomes after spinal fusion for AIS have been studied extensively, the literature on PONV outcomes is scarce and incomplete. PONV is most commonly included as a secondary outcome in studies related to pain management. This study is the first to specifically identify evidence and recommendations for interventions or clinical practice that influence PONV in AIS patients undergoing PSF. Most interventions and clinical practices have conflicting or limited data to support them, whereas others have low-level evidence as to whether the intervention/clinical practice influences the incidence of PONV. We have identified the need for expanded research using PONV as a primary outcome in patients with AIS undergoing spinal fusion surgery.
There has been one controlled clinical trial of ganciclovir capsules for the prevention of CMV disease in transplant recipients. Laboratory data and adverse events reported during these trials are summarized below.

Laboratory Data: The following table shows the frequency of granulocytopenia (neutropenia) and thrombocytopenia observed:

The following table shows the frequency of elevated serum creatinine values in these controlled clinical trials:

In 3 out of 4 trials, patients receiving either ganciclovir-IV solution or ganciclovir capsules had elevated serum creatinine levels when compared to those receiving placebo. Most patients in these studies also received cyclosporine. The mechanism of impairment of renal function is not known. However, careful monitoring of renal function during therapy with ganciclovir capsules is essential, especially for those patients receiving concomitant agents that may cause nephrotoxicity.
Patients receive pembrolizumab IV over 30 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.
PURPOSE:To obtain a dental treating material capable of preventing progress of carious teeth and occurrence of halitosis and further capable of preventing pyorrhea alveolaris by adding an inorganic antimicrobial agent to a resin for forming dental prostheses and resin for filling carious teeth and kneading the resultant mixture. CONSTITUTION:A dental treating material obtained by adding an inorganic antimicrobial agent (e.g. Bactekiller(R)) nontoxic to human bodies to a resin for forming dental prostheses and a resin for filling carious teeth and kneading the resultant mixture. The Bactekiller(R) is prepared by adding antimicrobial metal ions to zeolite and capable of exhibiting better effects thereof under conditions of high humidities. Thereby, dental prostheses and dentures made from the above-mentioned dental treating material are capable of preventing proliferation of various germs, etc., during mounting thereof in the oral cavity and further preventing carious teeth, pyorrhea alveolaris, etc., and occurrence of halitosis without any activity of bacteria Streptococcus mutans, etc., even if food residues remain. Furthermore, since the antimicrobial agent is kneaded with the resins, washing can also be carried out and effects thereof can be sustained for a long period.
The invention belongs to the technical field of biology, and particularly discloses a large yellow croaker ferritin heavy chain antibacterial and insect-resistant fragment LcFet-H51 and application thereof. The amino acid sequence of LcFet-H51 is shown as SEQ ID NO.2, and the nucleotide sequence of the coding gene is shown as SEQ ID NO. 1. The applicant obtains ferritin heavy chain fragment LcFet-H51 by constructing a prokaryotic expression vector, inducing expression, crushing by ultrasonic wave and purifying. LcFet-H51 has killing effect on Staphylococcus aureus, vibrio parahaemolyticus, vibrio vulnificus and ciliate; and the antibacterial activity of LcFet-H51 is not affected basically when the temperature is 25-100 ℃ and the pH is 3-12 and the ultraviolet radiation is 15-60 min. In addition, lcFet-H51 has no hemolytic toxicity to blood cells of large yellow croaker. LcFet-H51 can be applied to biological control of bacterial and parasitic diseases of aquatic animals, and can also be used as an antibacterial agent, an insecticide and a feed additive.
The ICP4 protein of herpes simplex virus plays an important role in the transactivation of viral genes. The present invention discloses that ICP4 also has the ability to inhibit apoptosis. This function appears to reside in functional domain distinct from the transactivating function, as indicated by studies using temperature sensitive mutants of ICP4 that transactivating function at elevated temperatures. Also disclosed are methods for inhibition of apoptosis using ICP4 or an ICP4 encoding gene, such as an α4 gene, methods of inhibiting ICP4's apoptosis-inhibiting function, and methods for the production of recombinant proteins and treatment of HSV infections. Further, the present invention discloses that the HSV-1 mutant lacking the α4 gene, has a secondary mutation in the gene U s 3 specifying a protein kinase. Thus a functional U s 3, a viral gene encoding a protein kinase known to phosphorylate serine/theonine within a specific arginine rich consensus sequence, is required in order to block apoptosis. Also disclosed are methods for inhibition of apoptosis using U s 3 or an U s 3 encoding gene, methods of inhibiting U s 3's apoptosis-inhibiting function and methods for the production of recombinant proteins and treatment of HSV infections.
Participants will engage in active breaks led by a professional, where they will perform various exercises based on the guidelines provided by the Chilean safety association (ACHS). These breaks will have an average duration of 14-16 minutes per day and will take place from Monday to Friday for a period of 12 weeks.
A pneumatic tubing system for distribution of medical objects in a medical environment without a dedicated carrier. The system comprises a plurality of headwall stations, a sending or receiving station, at least one pump, and at least one controller. Each headwall station is adapted to be installed in a headwall structure proximate to a patient bedside. The sending or receiving station is connected to each of the headwall stations via pneumatic tubing. The at least one pump is adapted to create pressure differentiation within at least a subset of the pneumatic tubing. The at least one controller is adapted to selectively activate the at least one pump to route a medical object between the sending or receiving station and one of the headwall stations within the pneumatic tubing.
PROBLEM TO BE SOLVED: To obtain an apoptosis inducer highly safe and effective for treating and improving various diseases by including a fraction isolated, through a column using an amino group-containing packing agent, from a solution prepared by heating a lactulose syrup or lactose solution in the presence of an alkali. SOLUTION: This apoptosis inducer is obtained by including, as active ingredient, a fraction isolated, through a column using an amino group-contg. packing agent, from a solution prepared by heating a lactulose syrup or lactose solution in the presence of an alkali; wherein the amount of the fraction included is pref. 0.1 μg to 100 mg per g of the preparation. Specifically, it is preferable that the above fraction is obtained by the following procedure: a solvent [pref. a mixture of acetonitrile and water in the volume ratio of (60:40) to (90:10)] is passed through a column using an amino group-contg. packing agent and a solvent-diluted solution of the above solvent is also passed through the column while continuing passing the solvent, and the resulting elute is recovered and the aimed effective fraction is collected.  By the way, the dose of the inducer is 0.01 μg to 100 mg/kg body weight.
Similar to single-pass HDWLE, with a second segmental inspection after the first examination in the same session. Equipment is similar to 1.
BACKGROUND: Human papillomavirus (HPV) vaccines represent an important strategic opportunity to prevent cervical cancer in low-middle income countries, such as India. The economic evaluation of HPV vaccines is crucial to inform public-health decisions; however, the scarce economic evaluations from India have focused on the value for money of bivalent vaccines and took a healthcare perspective. The aim of this study is to conduct a cost-effectiveness analysis of all available HPV vaccines in India.
MATERIAL AND METHODS: The Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model was used to evaluate the cost-effectiveness of HPV vaccination of 12-year-old girls in India, from both healthcare and societal perspectives. Cervical cancer cases, deaths averted and the incremental cost per Disability Adjusted Life Years (DALY) averted were reported as primary outcomes. Sensitivity analysis was undertaken to handle any uncertainty or variability in the results.
RESULTS: Compared with no vaccination, the incremental cost per DALY averted was USD 362.78 for nonavalent vaccine, USD 393.16 for quadrivalent vaccine and USD 432.24 for bivalent vaccine from a healthcare perspective. From a societal perspective, the incremental cost per DALY averted was USD 334.28 for nonavalent vaccine, USD 364.67 for quadrivalent vaccine and USD 403.75 for bivalent vaccine. Assuming constant prices per dose for all vaccines, the nonavalent vaccine dominated both quadrivalent and bivalent vaccines, indicating that it is the more cost-effective strategy.
CONCLUSION: Vaccinating girls against HPV is a cost-effective strategy to reduce the incidence of cervical cancer and mortality due to cervical cancer in India.
In particular embodiments, a computing system may, in response to a ride request, match a ride requestor with a vehicle. The system may receive data associated with sensory output from sensors associated with the vehicle. The sensory output may be associated with at least the ride requestor while the requestor is at least partially within a passenger compartment of the vehicle. The system may extract features from the received data according to a machine-learning model, which may be trained using a set of training data, each of which may be associated with sensory output relating to one or more predetermined event types. The system may generate, using the machine-learning model and the extracted features, a score representing a likelihood that the received data is indicative of one of the predetermined event types. An alert may be generated based a determination that the score satisfies a predetermined criterion.
The "PLAN CUIDARTE" is an intervention aimed at addressing the hospital discharge of people with HF, based on the nursing theory of transitions of Afaf Meleis(46) and under the guidelines of Robin Whittemore for the systematic development of complex interventions for experimental type research in nursing. The PLAN CUIDARTE addresses the specific educational needs of HF patients, as established by the patients with HF, as established by international accreditation standards.
Background: malnutrition is a poor prognostic factor in inpatients. Its early detection, together to nutritional intervention, can improve clinical evolution. It is important to carry out nutritional screening, however, there is no gold standard, and CIPA (Control of Intakes, Proteins and Anthropometry) has been implemented in our setting. The GLIM criteria (Global Leadership Initiative on Malnutrition) aim to provide a global consensus that allows common criteria for malnutrition diagnosis. The objective of this study is to evaluate the diagnostic quality of the CIPA screening vs the GLIM criteria for malnutrition as well as to establish the prevalence of sarcopenia.

Methods: cross-sectional single-center study comparing the diagnostic quality of CIPA in the diagnosis of malnutrition or risk of presenting it in inpatients vs GLIM. Adults of both sexes with a hospital stay of more than three days and attached to one of the following departments will be included: general surgery, internal medicine, vascular surgery, digestive system, hematology, nephrology, pulmonology, oncology, neurology, traumatology. The diagnostic evaluation of malnutrition and functionality will be carried out after three days of hospital stay, once the CIPA screening has been carried out. The participation of the patients in the study will consist of performing the CIPA malnutrition screening to which the GLIM test will be added. For the CIPA test, the BMI (body mass index), albumin levels and percentage of decreased intake will be taken. For the GLIM test, phenotypic criteria such as non-voluntary weight loss and reduction in muscle mass will also be studied together with etiological criteria to which, in addition to those referred to for the CIPA test, the presence of inflammation will be added. The study consists of a first cross-sectional part that will be completed once the data of the 490 subjects selected through probabilistic sampling has been collected. The second part of the study will consist of the prospective follow-up of the patients and the variables will be analyzed with prognostic criteria.

Discussion: this study will evaluate the diagnostic quality of CIPA vs the GLIM criteria for malnutrition and will establish the prevalence of sarcopenia in inpatients.
STEPS UP is a centrally assisted stepped collaborative telecare management program within primary care. The STEPS UP intervention added to Optimized Usual Care (PCMH-BH; formerly RESPECT-Mil) in 4 ways: (1) care management enhancements; (2) stepped psychosocial treatment options (web, phone, in person); (3) electronic symptom registry for measurement-based treatment planning (symptoms are measured at regular intervals and care is intensified for patients with recurrent or persistent PTSD and/or depressive) and for telecare manager caseload and site performance monitoring; and (4) routine assisted review of patient, telecare manager, and site performance by a central psychiatrist and psychologist.
High-frequency oscillations (HFOs) of intracranial EEG (iEEG) have the potential to identify the surgical resection area/seizure onset zone (SOZ) in patients with drug-resistant epilepsy. However, multiple reports indicate that HFOs can be generated not only by epileptic cerebral tissue but also by non-epileptic sites often including eloquent regions such as motor, visual, and language cortices. In this project, the initial evidence of a recurrent waveform pattern is presented that may be sufficient to distinguish pathological HFOs from physiological ones. Specifically, the investigators show that the SOZ repeatedly generates sets of stereotypical HFOs with similar waveform morphology whereas the events recorded from out of SOZ were irregular. This morphological pattern served as a robust neurobiomarker to isolate SOZ from other brain areas in multiple patients consistently. While these promising preliminary results are in place, the functional utility of stereotyped HFOs in a closed-loop seizure control system remains unknown. As of today, not much is known whether the stereotyped HFOs generated by the SOZ can be detected with an implantable system. If this can be achieved, then HFOs can be strategically translated as a neurobiomarker into closed-loop seizure control applications. The investigators hypothesize that pathologic stereotyped HFOs can be captured with the implantable Brain Interchange (BIC) system of CorTec and spatial topography of these events can be utilized by the implantable system to deliver targeted electrical stimulation to achieve seizure control. Using an acute setup within the epilepsy monitoring unit (EMU), this project will investigate the feasibility of capturing stereotyped HFO events using the new BIC system and compare the detection results to those obtained with the commercially available amplifier (Aim-1). If the first phase (Aim-1) of the study becomes successful, later in the second phase (Aim-2), once again in the EMU, the investigators will deliver targeted electrical stimulation to those brain sites associated with stereotyped HFOs using the BIC.

During the entire study, the BIC system will not be implanted but used externally to assess the neural data through externalized electrodes and then deliver closed-loop stimulation. If the outcomes of the research in an acute setting become successful, the investigators will execute a clinical trial and run our methods with the implanted BIC system in a chronic ambulatory setting.